Difference between revisions of "Prostate-specific antigen"

Jump to navigation Jump to search
Line 20: Line 20:
**In another series, 48% of individuals with cancer had a PSAD >0.15 ng/ml.<ref name=pmid22482342>{{Cite journal  | last1 = Aganovic | first1 = D. | last2 = Prcic | first2 = A. | last3 = Kulovac | first3 = B. | last4 = Hadziosmanovic | first4 = O. | title = Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. | journal = Med Arh | volume = 66 | issue = 1 | pages = 41-4 | month =  | year = 2012 | doi =  | PMID = 22482342 }}
**In another series, 48% of individuals with cancer had a PSAD >0.15 ng/ml.<ref name=pmid22482342>{{Cite journal  | last1 = Aganovic | first1 = D. | last2 = Prcic | first2 = A. | last3 = Kulovac | first3 = B. | last4 = Hadziosmanovic | first4 = O. | title = Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. | journal = Med Arh | volume = 66 | issue = 1 | pages = 41-4 | month =  | year = 2012 | doi =  | PMID = 22482342 }}
</ref>
</ref>
 
**Difference between races have been noted; in those without prostate cancer:<ref name=pmid8998182/>
Difference between races have been noted; in those without prostate cancer:<ref name=pmid8998182/>
***0.19 +/- 0.03 ng/ml (blacks).
*0.19 +/- 0.03 ng/ml (blacks).
***0.11 +/- 0.01 ng/ml (whites).  
*0.11 +/- 0.01 ng/ml (whites).  


Better predictor than (unadjusted) serum PSA for:
Better predictor than (unadjusted) serum PSA for:
48,836

edits

Navigation menu